Search research articles
Contact Us
Filters
Showing results (121-130 of 778) with videos related to
Page
of 78
Sort By:
Bioorganic & Medicinal Chemistry
|
September 3, 2003
Synthesis of potent Ins(1,4,5)P3 5-phosphatase inhibitors by modification of myo-inositol 1,3,4,6-tetrakisphosphate
Stephen J Mills, Barry V L Potter
The Lancet. Oncology
|
April 4, 2018
The NHS and migrant patients with cancer
Sophie Williams, Erin Dexter, Jessica L Potter
Future Medicinal Chemistry
|
March 31, 2011
Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery
Mark P Thomas, Barry V L Potter
Psychosomatics
|
December 1, 1987
Patients with combined physical and psychiatric problems
J Misiaszek, M Crago, R L Potter
Current Opinion in Pediatrics
|
December 3, 2019
Challenges and solutions to the study of rare childhood tumors
Douglas Fair, Samara L Potter, Rajkumar Venkatramani
Current Heart Failure Reports
|
August 13, 2022
Cognitive Dysfunction in Heart Failure: Pathophysiology and Implications for Patient Management
Sylvia Ye, Quan Huynh, Elizabeth L Potter
The Journal of Thoracic and Cardiovascular Surgery
|
May 4, 2021
Commentary: Beyond the scope of randomized controlled trials: Navigating the sea of big data
Alexandra L Potter, Chi-Fu Jeffrey Yang
Life Sciences
|
January 1, 1997
Workshop: the use of muscarinic toxins in the study of muscarinic receptors
D Jerusalinsky, A Harvey, E Karlsson, et al.
The Journal of Biological Chemistry
|
January 5, 1996
Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin
J Narasimhan, J L Potter, A L Haas
Blood
|
December 1, 1994
The VLA-2 (alpha 2 beta 1) I domain functions as a ligand-specific recognition sequence for endothelial cell attachment and spreading: molecular and functional characterization
W F Bahou, C L Potter, H Mirza
Page
of 78
Search research articles
Search
Showing results (121-130 of 778) with videos related to
Sort By:
Page
of 78
Bioorganic & Medicinal Chemistry
|
September 3, 2003
Synthesis of potent Ins(1,4,5)P3 5-phosphatase inhibitors by modification of myo-inositol 1,3,4,6-tetrakisphosphate
Stephen J Mills, Barry V L Potter
The Lancet. Oncology
|
April 4, 2018
The NHS and migrant patients with cancer
Sophie Williams, Erin Dexter, Jessica L Potter
Future Medicinal Chemistry
|
March 31, 2011
Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery
Mark P Thomas, Barry V L Potter
Psychosomatics
|
December 1, 1987
Patients with combined physical and psychiatric problems
J Misiaszek, M Crago, R L Potter
Current Opinion in Pediatrics
|
December 3, 2019
Challenges and solutions to the study of rare childhood tumors
Douglas Fair, Samara L Potter, Rajkumar Venkatramani
Current Heart Failure Reports
|
August 13, 2022
Cognitive Dysfunction in Heart Failure: Pathophysiology and Implications for Patient Management
Sylvia Ye, Quan Huynh, Elizabeth L Potter
The Journal of Thoracic and Cardiovascular Surgery
|
May 4, 2021
Commentary: Beyond the scope of randomized controlled trials: Navigating the sea of big data
Alexandra L Potter, Chi-Fu Jeffrey Yang
Life Sciences
|
January 1, 1997
Workshop: the use of muscarinic toxins in the study of muscarinic receptors
D Jerusalinsky, A Harvey, E Karlsson, et al.
The Journal of Biological Chemistry
|
January 5, 1996
Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin
J Narasimhan, J L Potter, A L Haas
Blood
|
December 1, 1994
The VLA-2 (alpha 2 beta 1) I domain functions as a ligand-specific recognition sequence for endothelial cell attachment and spreading: molecular and functional characterization
W F Bahou, C L Potter, H Mirza
Page
of 78